ABSTRACT
INTRODUCTION
Ankylosing spondylitis is a chronic and infl ammatory condition, affecting the spine, sacroiliac and peripheral joints. Although classically thought of as a spinal and peripheral articular disease, extra-articular organs such as the eyes, lungs, neurological system, and heart may also be affected (1) . Association between ankylosing spondylitis and cardiac disorders have been suggested by many studies. Most frequent cardiovascular disorders reported include aortitis, aortic root abnormalities with aortic regurgitation, conduction system alterations and cardiomyopathies (2) . Cardiac involvement may be a result of sclerosing infl ammatory process which primarily involves aortic root and aortic valve cusps (3, 4) . Fibrosis may also extend below the level of aortic valve through anterior mitral leafl et and septum causing mitral regurgitation and conduction disorders (3, 5) . Myocardial involvement is suggested to be a result of diffuse increase in myocardial connective tissue which may give rise to diastolic, and in advanced cases systolic dysfunction (2, 6) .
There are confl icting data regarding the prevalence of cardiovascular pathologies in patients with ankylosing spondylitis. It has been estimated that cardiac manifestations in patients with ankylosing spondylitis are found in 2-10% of patients; however, some studies have reported similar rate of cardiovascular abnormalities compared with normal population (7) (8) (9) (10) . Effects of co-existing cardiovascular risk factors, such as hypertension, may be a contributing factor for these confl icting data.
The aim of this study is to evaluate independent effects of ankylosing spondylitis on cardiac functions by examining electrocardiographic and echocardiographic data of outpatient ankylosing spondylitis patients without cardiovascular risk factors. The data of ankylosing spondylitis patients are compared with the ones of age-and gender matched healthy controls.
PATIENTS and METHODS

Patients
Thirty seven ankylosing spondylitis patients without any cardiovascular risk factors were recruited to this cross sectional study (28 male, 9 female; mean age: 41.3 ± 11.1 years). Patients were consecutively selected among patients of the physical medicine and rehabilitation outpatient clinic of our hospital. Twenty-eight healthy subjects who were recruited from hospital staff constituted our control group (19 male, 9 female; mean age: 40.1 ± 10.5 years). A detailed medical story, physical examination, chest X-ray and 12-lead electrocardiography were obtained from all patients. Erythrocyte sedimentation rates (ESR), serum Creactive protein (CRP) levels, Bath ankylosing spondylitis disease activity index (BASDAI) scores, disease durations and concurrent medications of ankylosing spondylitis patients as non-steroid anti-infl ammatory drugs and anti-TNF agents were recorded. Patients with classical cardiovascular risk factors were excluded from the study. Other exclusion criteria were evidence of ischemia on electrocardiograms and history of coronary artery disease, rheumatic valvular heart disease and atrial fi brillation. All subjects gave written informed consent and the institutional ethical committee approved the study protocol.
Cardiovascular Risk Factors
Based on the criteria used previously in similar studies, diabetes mellitus was diagnosed when patients were taking hypoglycemic medications or when, in the absence of treatment, fasting blood glucose levels were higher than 126 mg/dL in two consecutive determinations (11) (12) (13) . Hyperlipidemia was defi ned as fasting total serum cholesterol more than 240 mg/dL and/or when patients were taking an oral lipid-lowering agent. Subjects currently taking antihypertensive drugs or showing a systolic blood pressure of 140 mmHg or more and/or a diastolic blood pressure of 90 mmHg or more, based on the average of two or more readings taken in the sitting position at different days before investigation were defi ned as hypertensive. Patients smoking at least one cigarette daily for one year within the last fi ve year were considered smokers.
Echocardiography
All echocardiographic examinations were performed by the same operator who was blinded to clinical data by using cardiac ultrasound machine Vivid Four (GE-Vingmed Ultrasound ankylosing spondylitis Horten, Norway) equipped with a multifrequency transducer. Two-dimensional echocardiography, pulsed and continuous wave Doppler, and color fl ow Doppler studies were performed using standard techniques on each patient. All patients were in sinus rhythm at the time of examination and all measurements were calculated from three consecutive cycles and average of the three measurements was recorded.
Left ventricular end-diastolic (LVEDD) and end-systolic (LVESD) diameters were determined with M-mode echocardiography under two-dimensional guidance in the parasternal long-axis view, according to the recommendations of the American Society of Echocardiography (14) . Left ventricular ejection fraction (LVEF) was calculated from apical four-chamber view, using Simpson's biplane method. Pulsed wave tissue Doppler imaging (TDI) was performed to assess both LV and RV longitudinal functions. In apical four-chamber view, a 5 mm pulsed Doppler sample volume was placed on the mitral annulus at the septal and lateral sites and on the tricuspid annulus at the place of attachment of the anterior leafl et of the tricuspid valve. To minimize the angle between the beam and the direction of annular motion, care was taken to keep the ultrasound beam perpendicular to the plane of the annulus. Peak systolic (S'), early and late diastolic myocardial velocities (E' and A') were recorded. Left ventricular mean E' value was calculated by using E' velocities obtained from septal and lateral mitral annular sites. Left ventricular mean E' value was used for calculation of left ventricle E/E' ratio.
Electrocardiographic Measurements
All standard 12-lead ECG's were obtained using a recorder (Schiller AT-2 plus, Switzerland) set at a 50 mm/s paper speed and 1 mV/cm standardization. A single cardiologist who was blinded to clinical status of patients measured ECG intervals. Three consecutive cycles were measured in each of the standard 12 leads and from three values a mean of the parameter was calculated and included in the analysis.
Basal measurements: PR intervals, QRS intervals and RR intervals of all patients were recorded.
p-wave dispersion (Pwd) measurements:
The beginning of p-wave was defi ned as the point where the initial defl ection of p-wave crossed the isoelectric line and the end of p-wave was defi ned as the point where the fi nal defl ection of the p-wave crossed the isoelectric line. p-maximum was determined as the p-wave duration in any lead with the longest interval and p-minimum was determined as the p-wave duration in any lead with shortest interval. p-wave dispersion was calculated by substracting the minimum p-wave duration (p min ) from the maximal p-wave duration (p max ). In all patients derivations were excluded if the beginning or the ending of the p-wave could not be clearly identifi ed. Only recordings with more than eight analyzable leads were included.
QT and QT dispersion measurements:
The QT interval was measured from the onset of the QRS complex to the end of the T wave, defi ned as the return to the T-P isoelectrical line. If a U wave was present, the QT interval was measured to the nadir between the T and the U waves. If the T waves were isoelectric or of very low amplitude, that lead was excluded. Only recordings with more than eight analyzable leads were included. QT maximum was determined as the QT interval in any lead with the longest interval and QT minimum was determined as the QT interval in any lead with shortest interval. Measured QT intervals were corrected for heart rate with Bazett's formula (QTc = QT/√RR). Corrected QTd (QTcd) was defi ned as the difference between corrected maximum (QTc max ) and minimum QT (QTc min ) interval among the 12 ECG leads.
Statistics
Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA) version 11.0 was used for data analysis. Distribution of data was assessed by using one-sample Kolmogorov-Smirnov test. Values displaying normal distribution were expressed as the mean ± SD while values not displaying normal distribution were expressed as median (interquartile range). Signifi cance of difference between groups regarding numeric variables with normal distribution was tested with independent samples Student's t-test. Signifi cance of difference between groups regarding numeric variables without normal distribution was tested with Mann-Whitney U test. A p value less than 0.05 was considered signifi cant.
RESULTS
There were no signifi cant differences between patients and controls with respect to age and gender (28 male, mean age: 41.3 ± 11.1 years vs. 19 male, mean age: 40.1 ± 10.5 years, respectively; p= 0.33 for gender and p= 0.66 for age). The laboratory and clinical characteristics of ankylosing spondylitis patients is shown on Table 1 .
There were no signifi cant differences between ankylosing spondylitis patients and controls regarding M-mode, 2D and Doppler mitral infl ow parameters ( Table 2) . Two patients in the control group (7.2%) and 2 (5.4%) patients in the ankylosing spondylitis group had minimal aortic regurgitation (p= 0.51). Three subjects in the control group (10.7%) and 4 (10.8%) patients in the ankylosing spondylitis group had minimal mitral regurgitation (p= 0.65).
There were also no signifi cant differences regarding tissue Doppler velocities obtained at the level of mitral and tricuspid annulus between ankylosing spondylitis patients and controls (Table 3) .
Results of electrocardiographic analysis of patients and controls are shown on Table 4 . There were no significant differences between groups regarding PR intervals, QRS intervals and p wave and QTc dispersion values. One (2.7%) patient in the ankylosing spondylitis group and 2 (7.1%) patients in the control group had fi rst degree AV block (p= 0.41). Five (13.5%) patients in the ankylosing spondylitis group and 4 (14.3%) patients in the control group had incomplete right bundle branch block (p= 0.60). Two (5.4%) patients in the ankylosing spondylitis group and 1 (3.6%) patient in the control group had left anterior hemi-block (p= 0.60). None of the subjects in the study population had complete right or left bundle branch block. Two (5.4%) patients in the ankylosing spondylitis group displayed ventricular extrasystoles while none of control subjects displayed ventricular extrasystoles on their ECG's (p= 0.32). Neither patients nor controls displayed any supraventricular extrasystoles on their ECG's.
DISCUSSION
There were no signifi cant differences between ankylosing spondylitis patients without cardiovascular risk factors and control subjects regarding cardiac functions as evaluated by echocardiographic and electrocardiographic parameters in our study. There were also no signifi cant differences regarding rate of aortic or mitral valve regurgitation.
Several studies have shown higher rate of aortic valve regurgitation, conduction disturbances and cardiomyopathies in patients with ankylosing spondylitis compared to the normal population (2, 7) . However, symptomatic cardiac involvement is rarely seen in practice and there are confl icting data regarding the prevalence of cardiovascular pathologies in patients with ankylosing spondylitis. The prevalence of aortic root disease and valve disease associated with ankylosing spondylitis has been reported to range from 24% to %100 in postmortem series and 8% to 31% by transthorasic echocardiography (3, (15) (16) (17) (18) (19) . Aort diameters of ankylosing spondylitis patients were similar with the ones of controls in our study and only two ankylosing spondylitis patients had minimal aortic valve regurgitation (5.4%).
The rate of conduction disorders of ankylosing spondylitis patients as atrioventricular and bundle branch blocks in the literature vary between 3% and 23% (10, 20) .
(21.6%) Eight patients in the ankylosing spondylitis group displayed fi rst degree atrioventricular block or incomplete right bundle branch block or left anterior hemiblock in our study. However, there were no signifi cant differences regarding rate of atrioventricular and bundle branch blocks between patients and controls and none of the ankylosing spondylitis patients displayed clinically signifi cant conduction disorders. QRS and PR durations of patients and controls were also similar which argues against the suggestion of ankylosing spondylitis related myocardial fi brosis to be the cause of conduction disturbances observed in ankylosing spondylitis patients. The dispersion of ventricular repolarization from the surface electrocardiogram has been proposed as a simple non-invasive marker of susceptibility to ventricular arrhythmias (21) (22) (23) . One study reported increased QT dispersion (QTd) in ankylosing spondylitis patients; however another study found similar QTd between ankylosing spondylitis patients and controls (10, 24) . p wave dispersion (PWd) has been suggested to have predictive value for atrial fi brillation and two studies evaluating PWd in ankylosing spondylitis patients reported discrepant results (10, 25) . We also found similar QTd and PWd values between ankylosing spondylitis patients and controls, which may imply similar arrhythmia tendency of ankylosing spondylitis patients and controls in our study.
Diastolic dysfunction is also a frequently reported abnormality in ankylosing spondylitis patients and myocardial fi brosis related with the disease process has been suggested to be responsible factor (2) . However, effects of other possible factors like hypertension and signifi cant valvular pathologies should be excluded to relate diastolic dysfunction with ankylosing spondylitis. Mitral infl ow parameters and tissue Doppler velocities of ankylosing spondylitis patients without any cardiovascular risk factors were similar with the ones of control subjects in our study. E/E' ratio, which is suggested to be a reliable predictor of ventricular compliance, was also similar between our patients and controls (26) .
Our results are in agreement with the results of Brunner et al. who examined 100 male subjects with diagnosed ankylosing spondylitis for over 15 years (9) . They evaluated cardiac abnormalities of these patients with resting ECG and echocardiography as in our study and compared their results with results from the literature in the normal population. They found no signifi cant differences regarding the rates of valve regurgitation, conduction blocks and arrhythmia. They reported higher prevalence of diastolic dysfunction in ankylosing spondylitis patients however much of these patients were relatively older and had co-existing hypertension, which are two important risk factors for diastolic dysfunction. They suggested that impact of cardiac abnormalities in patients with ankylosing spondylitis might have been overestimated in the past and they argued against routine cardiologic evaluation with echocardiography in these patients. Hypertensive patients were excluded in our study and age and gender matched control group was used which excluded effects of age, gender, hypertension and other cardiovascular risk factors on the presence of diastolic dysfunctions and conduction disorders.
The cause of discrepancy regarding the prevalence of cardiovascular pathologies of ankylosing spondylitis patients in the literature is not clear. Effects of coexisting cardiovascular risk factors, effects of anti-infl ammatory therapy and heterogeneity regarding disease durations and activities may be contributing factors. Most of our patients were on anti-infl ammatory therapy and their ESR and CRP levels were low which may be a refl ection of suppressed infl ammatory activity. Roldan et al. studied the root and valves in ankylosing spondylitis patients using transesophageal echocardiography and found markedly increased rate of aortic root and valve disease compared with controls (3) . During follow up of 25 patients over 39 months in this study, in up to 24% new aortic root or valve abnormalities developed, in 12% existing valve regurgitation worsened signifi cantly and in 20% abnormalities resolved which demonstrates dynamic nature of ankylosing spondylitis related cardiac infl ammatory activity. Therefore, it may be hypothesized that anti-infl ammatory medications of patients may have suppressed cardiac infl ammation and related cardiac abnormalities in our study. Unfortunately, to our knowledge, no studies have been performed evaluating the usefulness of anti-infl ammatory medications in halting the progression of the disease. Therefore, further research is necessary to test our hypothesis.
Our study was a cross sectional study and patients were consecutively selected among patients who had been followed by the diagnosis of ankylosing spondylitis. HLA-B27 status was unknown for majority of patients. This may also be concerned with our observations since presence of HLA-B27 is suggested to be related with ankylosing spondylitis related cardiac complications as severe conduction disturbances and aortic valve regurgitation (27, 28) .
Limitations
Small sample size is main limitation of this study. In addition, our study was a cross-sectional study and there was heterogeneity regarding the duration of ankylosing spondylitis between patients. HLA-B27 status was unknown for majority of patients. We were unable to perform Holter examination in our study, which precluded assessment of arrhythmia prevalence and cardiac autonomic functions of ankylosing spondylitis patients. However, we examined QT and p wave dispersions on ECG's which are supposed to refl ect tendency for arrhythmia. In our opinion, it would be more interesting if the cohort would be prospectively followed to unmask potential cardiac interrelation.
Conclusion
There was no electrocardiographic or echocardiographic evidence of structural myocardial alterations in a small sample of ankylosing spodylitis patients without cardiovascular risk factors in our study. Our results are in agreement with the notion that impact of cardiac abnormalities in patients with ankylosing spondylitis might have been overestimated in the past. Further large-scale and prospective studies are needed to reach a conclusion regarding cardiovascular effects of ankylosing spondylitis and the effects of disease related anti-infl ammatory medications on possible cardiovascular complications of ankylosing spondylitis.
